Literature DB >> 26697439

Chinese guidelines on the management of renal cell carcinoma (2015 edition).

Jun Guo1, Jianhui Ma1, Yan Sun1, Shukui Qin1, Dingwei Ye1, Fangjian Zhou1, Zhisong He1, Xinan Sheng1, Feng Bi1, Dengfeng Cao1, Yingxia Chen1, Yiran Huang1, Houjie Liang1, Jun Liang1, Jiwei Liu1, Wenchao Liu1, Yueyin Pan1, Yongqian Shu1, Xin Song1, Weibo Wang1, Xiuwen Wang1, Xiaoan Wu1, Xiaodong Xie1, Xin Yao1, Shiying Yu1, Yanqiao Zhang1, Aiping Zhou1.   

Abstract

Entities:  

Year:  2015        PMID： 26697439      PMCID： PMC4671863          DOI： 10.3978/j.issn.2305-5839.2015.11.21

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  115 in total

1.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 2.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

3.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Thomas E Hutson; Bernard Escudier; Emilio Esteban; Georg A Bjarnason; Ho Yeong Lim; Kenneth B Pittman; Peggy Senico; Andreas Niethammer; Dongrui Ray Lu; Subramanian Hariharan; Robert J Motzer
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

4.  [Optimal margin in nephron-sparing surgery for renal cell carcinoma 4 cm or less in diameter].

Authors:  Quan-lin Li; Hong-wei Guan; Li-zhi Zhang; Qiu-ping Zhang; Fa-peng Wang; Yong-ji Liu
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2003-02

5.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Authors:  S A Rosenberg; J C Yang; D E White; S M Steinberg
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

6.  Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization.

Authors:  Ximing J Yang; Ming Zhou; Ondrej Hes; Steven Shen; Rongshan Li; Jose Lopez; Rajal B Shah; Yu Yang; Shang-Tian Chuang; Fan Lin; Maria M Tretiakova; Eric J Kort; Bin Tean Teh
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

7.  Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.

Authors:  John D Hainsworth; Mark S Rubin; Edward R Arrowsmith; James Khatcheressian; Edward J Crane; Luis A Franco
Journal:  Clin Genitourin Cancer       Date:  2013-05-09       Impact factor: 2.872

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.

Authors:  Mukul Minocha; Varun Khurana; Bin Qin; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2012-05-23       Impact factor: 5.875

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  8 in total

1.  MicroRNA-142-5p promotes cell growth and migration in renal cell carcinoma by targeting BTG3.

Authors:  Lingqi Liu; Shuchao Liu; Qixin Duan; Liang Chen; Tianpeng Wu; Huijun Qian; Sixing Yang; Dianqi Xin; Zhisong He; Yinglu Guo
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

2.  MicroRNA-30a-3p functions as a tumor suppressor in renal cell carcinoma by targeting WNT2.

Authors:  Lingqi Liu; Liang Chen; Tianpeng Wu; Huijun Qian; Sixing Yang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

3.  In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.

Authors:  Haixing Mai; Jun Huang; Yuanyuan Zhang; Nang Qu; Hengyan Qu; Guo-Hui Mei; Jiannan Liu; Xiaojie Xu; Lijun Chen
Journal:  Oncotarget       Date:  2017-06-27

4.  Clival metastasis of renal clear cell carcinoma: Case report and literature review.

Authors:  Wei-Qi Zhang; Yue Bao; Bo Qiu; Yong Wang; Zhi-Peng Li; Yi-Bao Wang
Journal:  World J Clin Cases       Date:  2018-09-06       Impact factor: 1.337

5.  Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study.

Authors:  Jianhui Chen; Wen Ye; Wei Jiang; Xiaofan Li; Rong Liu; Bijuan Lin; Jingnan Xiang; Wei Tian; Junjie Bai; Teng Zuo; Bingxin Lin; Yinan Guo; Song Zheng
Journal:  Transl Androl Urol       Date:  2021-03

6.  Analysis of surgical outcomes in 102 patients with renal cell carcinoma with venous tumor thrombus: A retrospective observational single-center study.

Authors:  Zuzanna Horynecka; Beata Jabłońska; Adam Kurek; Andrzej Lekstan; Michał Piaszczyński; Sławomir Mrowiec; Grzegorz Oczkowicz; Robert Król
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

7.  RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis.

Authors:  Lin Yang; Anna Alyasova; Dingwei Ye; Antonia Ridolfi; Luca Dezzani; Robert J Motzer
Journal:  BMC Cancer       Date:  2018-02-17       Impact factor: 4.430

8.  The tumor suppressor role of microRNA-338-3p in renal cell carcinoma.

Authors:  Yidong Huang; Yang Wu; Li Zeng; Wei Shan; Lugang Huang
Journal:  Oncol Lett       Date:  2018-06-06       Impact factor: 2.967
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.